# US 2003/0215429 A1 · Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215429 A1
- Document ID: US20030215429A1
- Status: Published application
- Kind: A1
- Application number: 10/400,675
- Filed: 2003-03-28
- Published: 2003-11-20
- Earliest claimed: 1998-02-20
- Assignees: Mendes Inc.
- Inventors: Claudio De Simone
- Web page: https://patentgrep.com/patent/US20030215429A1

## CPC

- C12N 1/205: Bacterial isolates
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12R 2001/24: Lactobacillus brevis
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

Disclosed is the use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction, and pharmaceutical or dietetic compositions containing such bacteria. Also disclosed is a strain of Lactobacillus brevis highly endowed with arginine deiminase.

## Claims

### Claim 1

A strain of lactic bacteria characterised by an activity of arginine deiminase, expressed as picomols citrulline/mg bacterial proteins/min. of not less than 0.1, and their descendants, mutants and derivatives which retain said activity, wherein said lactic bactria strain is selected from the group consisting of Lactobacillus brevis, Lactobacillus fermentum and Lactobacillus casei.

### Claim 2 (depends on 1)

The strain according to claim 1 which is the strain Lactobacillus brevis CD2 deposited with the DSM-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Brunswick, Germany, under the access number DSM 11988.

### Claim 3

Use of Gram-positive, Gram-negative and lactic bacteria sleected from the group consisting of the species L. brevis, L. fermentum and L. cesei, endowed with arginine deiminase, to prepare a pharmaceutical or dietetic composition capable of inducing apoptosis and/or reducing an inflammatory reaction and/or producing a curative effect in intestinal malabsorption and pancreatic insufficiency with modulation of the metabolic and/or nutritional state of the subject to be treated.

### Claim 4 (depends on 3)

The use according to claim 3 wherein the lactic bacteria belong to the strain Lactobacillus brevis CD2 deposited with the DSM-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Brunswick, Germany, under the access number DSM 11988.

### Claim 5 (depends on 3, 4)

The use according to claims 3 or 4 in the prevention and treatment of tumours in general and in particluar colon-rectal cancer, cancer of the lier, gliomae, neuroblatomae, squamocellular oral carcinoma, lymphoid tumours, cancer of the prostate gland, cancer of the bladder, cancer of the breast, cancer of the pleura and the peritoneum, serious myasthenia, systemic lupus erythematosus, and other auto-immune diseases including those of the thyroid, diseases characterised by acute and/or chronic inflammatory processes, bronchial asthma, intestinal inflammatory diseases, gastrites, duodenites, gastric ulcers, duodenal ulcers, pneumonias and pleurisies, infections from adenovirus, baculovirus and in general supported by a viral agent, diseases characterised by acute and/or chronic inflammatory and/or degenerative processes of the central and/or peripheral nervous system, pancreatites, endomyocardites and ischaemic damage (myocardiac, retinal, cerebral and renal), urolithiases, nephrocalcinoses, hyperoxaluria, hyperphosphaturia, nephroalteration in the systemic and/or district arterial and/or venous pressure such as portal hypertension vaginoses and vaginites procto-haemerrhoidal inflammations, prostates, sinusites and otites, conjunctivities, gingivites, periodontopathy, anaphylactic phenomena and immunodeficiencies.

### Claim 6 (depends on 3, 4, 5)

The use according to claims 3-5 wherein the bacteria are administered individually or in combination with each other or with Lactobacillus acidophilus, Lactobacillus buchneri, Lactobacillus casei, Lactobacillus catenaforme, Lactobacillus cellobiosus, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus jensenii, Lactobacillus leichmanii, Lactobacillus minutus, Lactobacillus plantarum, Lactobacillus rogosae, Lactobacillus salivarius, Bifidobacterium adolescentis, Bifidobacterium angulatum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium eriksonii, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium plantarum, Bifidobacterium pseudo-catenulatum, Bifidobacterium pseudolongum, Streptococcus lactis, Streptococcus raffinolactis, Streptococcus thermophilus, Acidaminococcus fermenta, Cytophaga fermentans, Rhodoferax fermentans, Cellulomonas fermentans and Zymomonas mobilis and/or in association with arginine deiminase, sphingomyelinase or other enzymes, with cortisone, anti-inflammatory, immuno-modulant, cytostatic, immunological, endocrinological, vascular, anaesthetic, and vasodilatory drugs, growth factors, cytokines, ceramides, vitamins and minerals, lipids, amino acids and carbohydrates, formulations for enteric use and dietetic, prebiotic or probiotic supplements, and with pharmacologically or dietetically acceptable.

### Claim 7 (depends on 3, 4, 5, 6)

The use according to any one of claims 3-6 wherein the bacteria are lyophilised or sonicated.

### Claim 8

A pharmaceutical composition which can be administered enterally, topically, rectally, nasally or parenterally, to induce apoptosis and/or reduce an inflammatory reaction, which comprises a quantity of Gram-positivie, Gram-negative and lactic bacteria selected from the group consisting of L. brevis, L. fermentum and L. casei endowed with arginine deiminase effective to induce apoptosis and/or reduce an inflammatory reaction and/or produce a curative effect in intestinal malabsorption and in pancreatic insufficiency with modulation of the metabolic and/or nutritional state of the subject to be treated.

### Claim 9 (depends on 8)

The composition according to claim 8 wherein the lactic bacteria belong to the strain Lactobacillus brevis CD2 deposited with the DSM—Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Brunswick, Germany, under the access number DSM 11988.

### Claim 10 (depends on 8, 9)

The composition according to claims 8 or 9 wherein the bacteria are lyophilised or sonicated.

### Claim 11 (depends on 8, 9, 10)

The composition according to any one of claims 8 to 10 wherein the concentration of the bacteria is from 1×101 CFU to 1×1013 CFU per gram of composition.

### Claim 12 (depends on 8, 9, 10, 11)

The composition according to any one of claims 8 to 11 for the prevention and treatment of tumours in general and in particular colon-rectal cancer, cancer of the liver, gliomae, neuroblastomae, squamocellular oral carcinoma, lymphoid tumours, cancer of the prostate gland, cancer of the bladder, cancer of the breast, cancer of the pleura and the peritoneum, serious myasthenia, systemic lupus erythematosus, and other auto-immune diseases including those of the thyroid, diseases characterised by acute and/or chronic inflammatory processes, bronchial asthma, intestinal inflammatory diseases, gastrites, duodenites, gastric ulcers, duodenal ulcers, pneumonias and pleurisies, infections from adenovirus, baculovirus and in general supported by a viral agent, diseases characterised by acute and/or chronic inflammatory and/or degenerative processes of the central and/or peripheral nervous system, pancreatites, endomyocardites and ischaemic damage (myocardiac, retinal, cerebral and renal), urolithiases, nephrocalcinoses, hyperoxaluria, hyperphosphaturia, nephroalteration in the systemic and/or district arterial and/or venous pressure such as portal hypertension, vaginoses and vaginites, procto-haemerrhoidal inflammations, prostates, sinusites and otites, conjunctivites, gingivites, periodontopathy, anaphylactic phenomena and immunodeficiencies.

### Claim 13 (depends on 8, 9, 10, 11, 12)

A composition according to any one of claims 8 to 12 wherein the bacteria are administered individually or in combination with each other or with Lactobacillus acidophilus, Lactobacillus buchneri, Lactobacillus casei, Lactobacillus catenaforme, Lactobacillus cellobiosus, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus jensenii, Lactobacillus leichmanii, Lactobacillus minutus, Lactobacillus plantarum, Lactobacillus rogosae, Lactobacillus salivarius, Bifidobacterium adolescentis, Bifidobacterium angulatum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium eriksonii, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium plantarum, Bifidobacterium pseudo-catenulatum, Bifidobacterium pseudolongum. Streptococcus lactis, Streptococcus raffinolactis, Streptococcus thermophilus, Acidaminococcus fermenta, Cytophaga fermentans, Rhodoferax fermentans, Cellulomonas fermentans and Zymomonas mobilis or in combination with arginine deiminase, sphingomyelinase or other enzymes, with cortisone, anti-inflammatory, immuno-modulant, cytostatic, immunological, endocrinological, vascular, anaesthetic, and vasodilatory drugs, growth factors, cytokines, ceramides, vitamins and minerals, lipids, amino acids and carbohydrates, formulations for enteric use and dietetic, prebiotic or probiotic supplements, and with pharmacologically or dietetically aceptable excipients.
